Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy

  • Byeonggu Han
  • Hee-Chul Ahn
Part of the Methods in Molecular Biology book series (MIMB, volume 1360)


During the past decade fragment-based drug discovery (FBDD) has rapidly evolved and several drugs or drug candidates developed by FBDD approach are clinically in use or in clinical trials. For example, vemurafenib, a V600E mutated BRAF inhibitor, was developed by utilizing FBDD approach and approved by FDA in 2011. In FBDD, screening of fragments is the starting step for identification of hits and lead generation. Fragment screening usually relies on biophysical techniques by which the protein-bound small molecules can be detected. NMR spectroscopy has been extensively used to study the molecular interaction between the protein and the ligand, and has many advantages in fragment screening over other biophysical techniques. This chapter describes the practical aspects of fragment screening by saturation transfer difference NMR.

Key words

Fragment Fragment-based drug discovery Kinase Optimum solubility screening NMR screening Saturation transfer difference Surface plasmon resonance X-ray crystallography 



This work was supported by the GRRC program of Gyeonggi province [(GRRC-DONGGUK2014-B02), diseasesDevelopment of novel recombinant enzymes and diagnostic platform].


  1. 1.
    Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39CrossRefPubMedGoogle Scholar
  2. 2.
    Cohen P, Alessi DR (2013) Kinase drug discovery—what’s next in the field? ACS Chem Biol 8:96–104PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–1534CrossRefPubMedGoogle Scholar
  4. 4.
    Murray CW, Verdonk ML, Rees DC (2012) Experiences in fragment-based drug discovery. Trends Pharmacol Sci 33:224–232CrossRefPubMedGoogle Scholar
  5. 5.
    Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041–3046PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Drysdale MJ, Brough PA (2008) Medicinal chemistry of Hsp90 inhibitors. Curr Top Med Chem 8:859–868CrossRefPubMedGoogle Scholar
  8. 8.
    Murray CW, Carr MG, Callaghan O et al (2010) Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 53:5942–5955CrossRefPubMedGoogle Scholar
  9. 9.
    Woodhead AJ, Angove H, Carr MG et al (2010) Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 53:5956–5969CrossRefPubMedGoogle Scholar
  10. 10.
    Wang YS, Strickland C, Voigt JH et al (2010) Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. J Med Chem 53:942–950CrossRefPubMedGoogle Scholar
  11. 11.
    Zhu Z, Sun ZY, Ye Y et al (2010) Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I-inhibitor design and validation. J Med Chem 53:951–965CrossRefPubMedGoogle Scholar
  12. 12.
    Baker M (2013) Fragment-based lead discovery grows up. Nat Rev Drug Discov 12:5–7CrossRefPubMedGoogle Scholar
  13. 13.
    Campos-Olivas R (2011) NMR screening and hit validation in fragment based drug discovery. Curr Top Med Chem 11:43–67CrossRefPubMedGoogle Scholar
  14. 14.
    Meyer B, Peters T (2003) NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl 42:864–890CrossRefPubMedGoogle Scholar
  15. 15.
    Mayer M, Meyer B (2003) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108–6117CrossRefGoogle Scholar
  16. 16.
    Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed Engl 38:1784–1788CrossRefGoogle Scholar
  17. 17.
    Streiff JH, Juranic NO, Macura SI et al (2004) Saturation transfer difference nuclear magnetic resonance spectroscopy as a method for screening proteins for anesthetic binding. Mol Pharmacol 66:929–935PubMedGoogle Scholar
  18. 18.
    Jancarik J, Pufan R, Hong C, Kim SH, Kim R (2004) Optimum solubility (OS) screening: an efficient method to optimize buffer conditions for homogeneity and crystallization of proteins. Acta Crystallogr D Biol Crystallogr 60:1670–1673CrossRefPubMedGoogle Scholar
  19. 19.
    Lau WF, Withka JM, Hepworth D et al (2011) Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. J Comput Aided Mol Des 25:621–636CrossRefPubMedGoogle Scholar
  20. 20.
    Probst GD, Bowers S, Sealy JM et al (2011) Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett 21:315–319CrossRefPubMedGoogle Scholar
  21. 21.
    Cee VJ, Cheng AC, Romero K et al (2009) Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorg Med Chem Lett 19:424–427CrossRefPubMedGoogle Scholar
  22. 22.
    Bennett BL, Sasaki DT, Murray BW et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98:13681–13686PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of PharmacyDongguk University-SeoulIlsandong-gu, GoyangRepublic of Korea

Personalised recommendations